These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30481748)

  • 1. LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway.
    Chen Y; Huang W; Sun W; Zheng B; Wang C; Luo Z; Wang J; Yan W
    Cell Physiol Biochem; 2018; 51(3):1313-1326. PubMed ID: 30481748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling.
    Wang Q; Liu MJ; Bu J; Deng JL; Jiang BY; Jiang LD; He XJ
    Life Sci; 2021 Mar; 268():118925. PubMed ID: 33358903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b.
    Sun Z; Zhang T; Chen B
    Med Sci Monit; 2019 Feb; 25():1410-1422. PubMed ID: 30793707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
    Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
    Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma.
    He R; Wu JX; Zhang Y; Che H; Yang L
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5857-5866. PubMed ID: 30280767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
    Sun ZY; Jian YK; Zhu HY; Li B
    Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
    Yang C; Wu K; Wang S; Wei G
    J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
    Ye F; Tian L; Zhou Q; Feng D
    Gene; 2019 Dec; 721():144093. PubMed ID: 31473323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA GAS5 Suppresses the Proliferation and Invasion of Osteosarcoma Cells via the miR-23a-3p/PTEN/PI3K/AKT Pathway.
    Liu J; Chen M; Ma L; Dang X; Du G
    Cell Transplant; 2020; 29():963689720953093. PubMed ID: 33121268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma.
    Wang Y; Zeng X; Wang N; Zhao W; Zhang X; Teng S; Zhang Y; Lu Z
    Mol Cancer; 2018 May; 17(1):89. PubMed ID: 29753317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway.
    Tong CJ; Deng QC; Ou DJ; Long X; Liu H; Huang K
    Aging (Albany NY); 2021 May; 13(16):20116-20130. PubMed ID: 34048366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis.
    Liu ZB; Wang JA; Lv RQ
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1418-1427. PubMed ID: 30840262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long Noncoding RNA FER1L4 Suppresses Tumorigenesis by Regulating the Expression of PTEN Targeting miR-18a-5p in Osteosarcoma.
    Fei D; Zhang X; Liu J; Tan L; Xing J; Zhao D; Zhang Y
    Cell Physiol Biochem; 2018; 51(3):1364-1375. PubMed ID: 30481787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling.
    He B; Peng F; Li W; Jiang Y
    J Cell Biochem; 2019 Mar; 120(3):2908-2918. PubMed ID: 30500989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis.
    Duan G; Zhang C; Xu C; Xu C; Zhang L; Zhang Y
    Int J Oncol; 2019 Jan; 54(1):17-28. PubMed ID: 30365098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y; Xiao G; Chen Y; Deng Y
    Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.
    Jiang N; Wang X; Xie X; Liao Y; Liu N; Liu J; Miao N; Shen J; Peng T
    Cancer Lett; 2017 Oct; 405():46-55. PubMed ID: 28642170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-493-5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel-like factor 5.
    Zhang Z; Luo G; Yu C; Yu G; Jiang R; Shi X
    J Cell Physiol; 2019 Aug; 234(8):13525-13533. PubMed ID: 30773645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
    Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
    J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of long non-coding RNA UCA1 represses tumorigenesis and metastasis of osteosarcoma via miR-513b-5p/E2F5 axis.
    Zhang Z; Wu X; Han Q; Huang Z
    Anticancer Drugs; 2021 Jun; 32(6):602-613. PubMed ID: 33595944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.